Inactive Instrument

Cellular Biomedicine Group, Inc.

Equities

CBMG

US15117P1021

Biotechnology & Medical Research

Cellular Biomedicine Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020

May 06, 2020 at 09:20 pm

Cellular Biomedicine Group, Inc. announced earnings results for the first quarter ended March 31, 2020. For the first quarter, the company announced sales was USD 0 compared to USD 49,265 a year ago. Operating loss was USD 11.430 million compared to USD 9.416 million a year ago. Net loss was USD 11.547 million compared to USD 9.336 million a year ago. Basic loss per share from continuing operations was USD 0.6 compared to USD 0.51 a year ago.

Latest news about Cellular Biomedicine Group, Inc.

Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate Nktr-255 in Combination with C-Til051 in Advanced Non-Small Cell Lung Cancer	27/09/23	CI
Cellular Biomedicine Group Announces FDA Clearance of Investigational New Drug Application for Novel TIL Therapy C-TIL051	31/10/22	CI
Cellular Biomedicine Group Inc Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma	12/01/22	CI
Cellular Biomedicine Group Inc. Receives FDA Clearance of IND Application for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma	13/12/21	CI
Cellular Biomedicine Group, Inc. announced that it has received $120 million in funding from CICC Capital Management Co., Ltd., AstraZeneca PLC, Investment Arm, Yunfeng Capital, GIC Pte. Ltd., TF Capital, Sequoia China Investment Management LLP and other investors	29/09/21	CI
Hillhouse Capital Provides Information to Shareholders of Hillhouse Capital	19/02/21	CI
Cellular Biomedicine : Completes Merger with CBMG Holdings; Shares to No Longer Trade on Nasdaq	19/02/21	MT
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from S&P Global BMI Index	19/02/21	CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from S&P TMI Index	19/02/21	CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from NASDAQ Composite Index	19/02/21	CI
A consortium of buyers completed the acquisition of remaining 52.34% stake in Cellular Biomedicine Group, Inc. from a group of shareholders.	18/02/21	CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell 2000 Defensive Index	18/02/21	CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell 2000 Dynamic Index	18/02/21	CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell 2000 Growth-Defensive Index	18/02/21	CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell 2000 Value-Defensive Index	18/02/21	CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell 2000 Index	18/02/21	CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell 3000 Index	18/02/21	CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell 2500 Index	18/02/21	CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell 2000 Growth Index	18/02/21	CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell 2000 Value Index	18/02/21	CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell Small Cap Completeness Index	18/02/21	CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell Small Cap Comp Value Index	18/02/21	CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell Small Cap Comp Growth Index	18/02/21	CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell 2500 Value Index	18/02/21	CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell 3000 Growth Index	18/02/21	CI

Chart Cellular Biomedicine Group, Inc.

Duration

Period

More charts

Company Profile

Cellular Biomedicine Group, Inc. (CBMG), is a clinical-stage biopharmaceutical company. The Company is leveraging its cell-based technologies to develop immunotherapies for the treatment of cancer and stem cell therapies for the treatment of degenerative diseases. The Company provides comprehensive and integrated research and manufacturing services throughout the discovery, development and manufacturing spectrum for cell-based technologies. The Company's primary focus has been to serve the growing health care market initially in China by marketing and commercializing immune cell and stem cell therapeutics, related tools and products. The Company's treatment focal points are cancer and Knee Osteoarthritis (KOA). It is focusing its clinical development efforts on assets such as C-CAR088, C-CAR039, TIL051, AFT-TCRT in China and/or United States. It has also completed a Phase-I/IIa clinical study, in China, for our KOA therapy named ReJoin.

Sector

Biotechnology & Medical Research

Calendar

03/06/2024 - American Society of Clinical Oncology Annual Meeting - Abstract Number: 4019

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+64.23%	62.59B
IQVIA HOLDINGS INC.	-2.31%	41.18B
LONZA GROUP AG	+45.66%	40.29B
CELLTRION, INC.	-8.29%	27.9B
ICON PUBLIC LIMITED COMPANY	+11.97%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.16%	19.09B
BIO-TECHNE CORPORATION	+7.54%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.72%	12.26B
MEDPACE HOLDINGS, INC.	+27.17%	12.05B

Other Biotechnology & Medical Research